M
Michael F. McDermott
Researcher at University of Leeds
Publications - 153
Citations - 16117
Michael F. McDermott is an academic researcher from University of Leeds. The author has contributed to research in topics: Familial Mediterranean fever & Tumor necrosis factor alpha. The author has an hindex of 55, co-authored 148 publications receiving 14562 citations. Previous affiliations of Michael F. McDermott include Royal London Hospital & National Institute for Health Research.
Papers
More filters
Journal ArticleDOI
Vitamin D3 down-regulates intracellular Toll-like receptor 9 expression and Toll-like receptor 9-induced IL-6 production in human monocytes
Laura J. Dickie,Leigh D Church,Lydia R. Coulthard,Rebeccah J. Mathews,Paul Emery,Michael F. McDermott +5 more
TL;DR: The intracellular TLRs are differentially regulated by vitamin D(3), with TLR9 being down-regulated by vitaminD(3) exposure whereas TLR3 was unaffected, which may have significant biological relevance and may be a factor in the association of vitamin D deficiency with susceptibility to autoimmune disease.
Journal Article
TNF and TNFR biology in health and disease
TL;DR: Developments include an understanding that the biological effects of the tumor necrosis factor-alpha (TNF-alpha or TNFSF) cytokine may be regulated by soluble TNF receptor binding and that modulation of receptor levels may permit physiological inhibition of TNF action.
Journal Article
Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders.
TL;DR: Canakinumab has promising clinical safety and pharmacokinetic properties, and demonstrated potential for the treatment of cryopyrin-associated periodic syndromes and possibly for other complex inflammatory diseases, such as rheumatoid arthritis, systemic-onset juvenile idiopathic arthritis (SoJIA), COPD disease and ocular diseases.
Journal ArticleDOI
Histone deacetylases are dysregulated in rheumatoid arthritis and a novel histone deacetylase 3-selective inhibitor reduces interleukin-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients.
Justin Gillespie,Sinisa Savic,C. Wong,Aiden Hempshall,Martyn Inman,Paul Emery,Ronald Grigg,Michael F. McDermott +7 more
TL;DR: HDAC activity is dysregulated in RA PBMCs and is a potential target for therapeutic intervention, as it is not affected by conventional anti-TNF treatment with etanercept, but further clinical characterization and evaluation for adverse effects is needed.